Alcobra Pharmaceuticals Ltd. (Nasdaq: ADHD) raised a gross $33 million in its secondary offering on Thursday. The company issued two million shares at $16.50 per share. The underwriters, Stifel Nicolaus, Aegis Capital Corp., JMP Securities have a 30-day option to buy additional 300,000 shares.
Alcobra will use the proceeds for the development of its proprietary drug, MG01CI (Metadoxine extended-release), for the treatment of ADHD and Fragile X Syndrome, a factor in autism.
Alcobra raised $27 million in its IPO in May.
Alcobra's share price closed at $17.01 on Friday, giving a market cap of $189 million, after falling 0.5% during the session.
Published by Globes [online], Israel business news - www.globes-online.com - on October 27, 2013
© Copyright of Globes Publisher Itonut (1983) Ltd. 2013